➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Dow
Harvard Business School
Express Scripts

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,270,989

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,270,989
Title: Protein production and delivery
Abstract:The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and .beta.-interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or .beta.-interferon. The invention further relates to a methods of producing pharmaceutically useful preparations containing thrombopoietin, DNase I, or .beta.-interferon from homologously recombinant cells and methods of gene therapy comprising administering homologously recombinant cells producing thrombopoietin, DNase I, or .beta.-interferon to a patient for therapeutic purposes.
Inventor(s): Treco; Douglas A. (Arlington, MA), Heartlein; Michael W. (Boxborough, MA), Hauge; Brian M. (Beverly, MA), Selden; Richard F (Wellesley, MA)
Assignee: Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:08/406,030
Patent Claims:see list of patent claims

Details for Patent 6,270,989

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2018-08-07 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2018-08-07 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2018-08-07 DISCN search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2018-08-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Transkaryotic Therapies, Inc. (Cambridge, MA) 2018-08-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Colorcon
Boehringer Ingelheim
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.